|
|
|
|
| LEADER |
01000cam a2200265 4500 |
| 001 |
1831784769 |
| 003 |
DE-627 |
| 005 |
20230717131436.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
230123s2023 xxu|||||o 00| ||eng c |
| 020 |
|
|
|a 1119789745
|9 1-119-78974-5
|
| 020 |
|
|
|a 9781119789741
|9 978-1-119-78974-1
|
| 020 |
|
|
|a 1119789729
|9 1-119-78972-9
|
| 020 |
|
|
|a 9781119789727
|9 978-1-119-78972-7
|
| 035 |
|
|
|a (DE-627)1831784769
|
| 035 |
|
|
|a (DE-599)KXP1831784769
|
| 035 |
|
|
|a (OCoLC)1366074201
|
| 040 |
|
|
|a DE-627
|b eng
|c DE-627
|e rda
|
| 041 |
|
|
|a eng
|
| 044 |
|
|
|c XD-US
|c XA-GB
|
| 082 |
0 |
|
|a 362.1962414
|
| 245 |
1 |
0 |
|a Coronavirus disease 2019 (Covid-19)
|b a clinical guide
|c edited by Ali Gholamrezanezhad, MD, Michael P. Dube, MD
|
| 264 |
|
1 |
|a Hoboken, NJ
|a Chichster, West Sussex
|b Wiley Blackwell
|c [2023]
|
| 264 |
|
4 |
|c © 2023
|
| 300 |
|
|
|a 1 Online-Ressource (701 pages)
|b Illustrationen, Diagramme
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Literaturangeben
|
| 505 |
8 |
0 |
|a Cover -- Title Page -- Copyright Page -- Contents -- List of Contributors -- Preface -- Chapter 1 COVID-19: Epidemiology -- Origin -- Animal Host -- Infectivity and Incubation -- Modes of Transmission -- Overview -- Respiratory Droplets -- Aerosolization -- Direct Surface Contact and Fomites -- Fecal-Oral -- Bloodborne -- Semen and Vaginal Secretions -- Asymptomatic Transmission -- Virulence and Mortality -- Case Fatality Rate -- Serial Interval -- Reproduction Number/Reproduction Ratio -- Excess Mortality -- Demographics -- Overview -- Age -- Sex -- Race and Ethnicity -- Disease Prevention -- Vaccinations -- Personal Protective Equipment: Respirators and Masks -- Physical Distancing -- Hand and Surface Sanitation -- Adequate Ventilation of Indoor Spaces -- Use of Outdoor Spaces -- Global Impacts -- Distribution -- International Response -- Future Outbreaks -- Conclusions -- References -- Chapter 2 COVID-19: Virology -- Coronaviruses -- Taxonomy -- Morphology -- Nucleic Acid -- Antigenicity -- SARS-CoV-2 -- Morphology and Nucleic Acid -- Spike Protein -- Origin -- Viral Transmission -- Variants -- References -- Chapter 3 COVID-19: Laboratory/Serologic Diagnostics -- Molecular Diagnostics for COVID-19 -- Nucleic Acid Amplification Testing -- RT-qPCR -- RT-LAMP -- CRISPR-Based Techniques -- Sequencing Techniques -- Antigen Testing -- Viral Culture -- Antibody Testing for COVID-19 -- Principles of Antibody Testing -- Antibody Assays for SARS-CoV-2 -- Assay Target Selection -- Binding Assays -- Neutralization Assays -- Antibody Assay Sensitivity and Specificity -- Humoral Response to SARS-CoV-2 Infection -- Kinetics of Antibody Response -- Antibody Response and Disease Severity -- Duration of Immunity -- Current and Potential Applications of Antibody-Based Tests in SARS-CoV-2 -- Management of Individual Disease and Sequelae Monitoring.
|
| 505 |
8 |
0 |
|a Contact Tracing -- Vaccine Efficacy -- Conclusions and Future Directions -- References -- Chapter 4 COVID-19: Radiologic Diagnosis -- Current Guidelines on When to Image -- Fleischner Society -- World Health Organization -- Practical Points -- Technical Considerations to Limit Spread While Imaging -- Chest Radiography -- Cross-Sectional Imaging -- Ultrasound -- Imaging by Modality -- X-Ray -- Computed Tomography -- Ultrasound -- PET -- MRI -- Guidelines for Reporting -- RSNA -- COVID-19 Reporting and Data System -- COVID-19 Imaging Reporting and Data System -- References -- Chapter 5 COVID-19: Pathology Perspective -- Gross and Histopathologic Findings in the Respiratory System -- Gross and Histopathologic Findings in the Cardiovascular System -- Histopathologic Findings in Kidney -- Histopathologic Findings in the Gastrointestinal Tract and Liver -- Histopathologic Findings in Brain -- Histopathologic Findings in Skin -- References -- Chapter 6 COVID-19: Immunology -- Anatomic Progression of COVID-19 -- Adaptive Immune Response in the Nasal Passages and the Lungs -- Immune Response to Immunization -- Immune Correlates of Protection from Infection -- Decline in Vaccine-Induced Immune Responses over Time -- Immune Consequences of Virologic Dissemination -- Autoantibodies Against Type I IFN -- Viral Evasion -- Immune Dysregulation -- Antibody-Dependent Cellular Cytotoxicity -- Cytokine Storm -- Conclusions -- Acknowledgments -- References -- Chapter 7 COVID-19: Presentation and Symptomatology -- Pulmonary Manifestations of COVID-19 -- Atypical Acute Respiratory Distress Syndrome -- Otolaryngologic Manifestations of COVID-19 -- Sense of Smell -- Voice Disorders -- Hearing, Tinnitus, and Facial Nerve -- Gastrointestinal Manifestation of COVID-19 -- Coronavirus and Pregnancy -- Physiologic Changes and Effect of SARS-CoV-2 Infection.
|
| 505 |
8 |
0 |
|a General Symptoms of COVID-19 in Obstetric Patients -- Impact of COVID-19 on Gestation: Maternal and Neonatal Outcomes -- Vertical Transmission and Possible Fetal Complications -- COVID-19 and Delivery -- Breastfeeding -- Vaccination -- Urologic Manifestations of COVID-19 -- Kidneys -- Genital and Lower Urinary Tract Infection -- Disorders of Genital Organ Function -- Infertility -- References -- Chapter 8 COVID-19: Risk Stratification -- Potential Biomarkers for COVID-19 Detection, Severity, and Mortality -- Host Risk Factors for COVID-19 -- ABO Blood Type as an Additional Risk Factor -- ABO Blood Group and Rh Factor -- Association of Blood Group with Viral Respiratory Diseases -- Association of Blood Type with Higher Susceptibility to COVID-19 Infection and Outcomes -- Genetic Association and Underlying Molecular Mechanisms -- ML Methods for X-Ray and CT Image Classification and Prediction -- References -- Chapter 9 COVID-19: Outpatient Management in Adults -- Potential Conflicts of Interest -- Initial Diagnosis -- Prognosis and Choice of Admission Versus Outpatient Management -- Home Monitoring -- Telehealth Diagnosis and Follow-up -- Pulse Oximetry Monitoring -- Post-Hospital Discharge Care -- General Management Issues -- Isolation -- Hydration and Nutrition -- Continuation of Ongoing Therapies -- Nutritional Supplements -- Anticoagulation -- Use of Home Supplemental Oxygen -- Antivirals and Anti-inflammatory Treatments -- Anti-SARS-CoV-2 mAbs -- Selection of Outpatients to Receive Anti-SARS-CoV-2 mAbs -- Bamlanivimab Plus Etesevimab -- Casirivimab Plus Imdevimab -- Sotrovimab -- Bebtelovimab -- Side Effects of Anti-SARS-CoV-2 mAbs -- Distribution of mAbs -- Oral Antivirals -- Molnupiravir -- Nirmatrelvir (PF-07321332)/Ritonavir -- Outpatient Anti-inflammatory Interventions -- Inhaled Budesonide -- Fluvoxamine -- Dexamethasone.
|
| 505 |
8 |
0 |
|a Drugs That Are Not Recommended for Outpatient Use -- Janus Kinase Inhibitors/Anti-IL-6 Therapies -- Chloroquine and Hydroxychloroquine -- Ivermectin -- Azithromycin -- Lopinavir/Ritonavir -- Convalescent Plasma -- Colchicine -- Summary -- References -- Chapter 10 COVID-19: Inpatient Management -- Respiratory Support for Hospitalized Patients with COVID-19 -- Noninvasive Respiratory Support -- Prone Positioning in Awake Patients -- Caring for the Critically Ill Patient with COVID-19 -- Practical Considerations for Intubating Patients -- Mechanical Ventilation of Patients with COVID-19 -- Rescue Therapies for Refractory Hypoxemia of Ventilated Patients -- Pharmacologic Therapies for Hospitalized Patients with COVID-19 -- Use of Antivirals in Patients Hospitalized for COVID-19 -- Anti-inflammatory Therapies for Hospitalized Patients with COVID-19 -- Therapies that Have No Benefit in Hospitalized Patients with COVID-19 -- Extrapulmonary Disease in Acutely Ill Patients with COVID-19 -- Thromboembolic Disease -- Cardiac Complications -- Renal Complications -- Infectious Complications -- Performing Aerosol-Generating Procedures in Patients with COVID-19 -- Bronchoscopy in COVID-19 -- Tracheostomy in Patients with COVID-19 -- Cardiopulmonary Resuscitation of the Patient with COVID-19 -- Coordinating Patient Placement and Care in COVID-19 Units -- Increasing ICU Capacity -- Additional Management Considerations -- References -- Chapter 11 COVID-19: ICU and Critical Care Management -- Epidemiology of Critically Ill Patients with COVID-19 Pneumonia -- Risk Factors for Severe Disease -- Mortality -- Infection Prevention and Control of COVID-19 in the ICU -- Aerosol-Generating Procedures -- Visitation -- Cardiopulmonary Resuscitation in COVID-19 -- Hemodynamic Support in COVID-19 -- Management of Respiratory Failure from COVID-19 -- Intubation.
|
| 505 |
8 |
0 |
|a Ventilator Management -- Prone Positioning -- Treatment of COVID-19-Associated ARDS with Corticosteroids -- Tocilizumab for Critical COVID-19 Illness -- Extracorporeal Membrane Oxygenation for COVID-19 ARDS -- Venous Thromboembolism and Anticoagulation in COVID-19 -- After the ICU: Challenges for Survivors of COVID-19 Critical Illness -- References -- Chapter 12 COVID-19 in Pediatrics -- Epidemiology -- Epidemiology of Multisystem Inflammatory Syndrome in Children -- Transmission in Children -- Neonatal Transmission -- Breastfeeding -- Clinical Manifestations -- Disease Severity -- Infection in Infants (Age < -- 1 Year) -- Cutaneous Manifestations -- COVID Toes -- Neurologic Symptoms -- Atypical Clinical Manifestations -- Imaging Findings -- MIS-C Clinical Manifestations -- Post-Acute Sequelae of SARS-CoV-2 (PASC) in Children -- Approach to Diagnosis -- Screening and Diagnosis in Symptomatic Patients -- Screening and Diagnosis in Asymptomatic Patients -- Neonatal Testing -- COVID-Recovered Patients -- Retesting of COVID-Recovered Patients -- Testing of COVID-19 Fully Vaccinated Persons -- MIS-C Diagnosis -- Hyperinflammation in COVID-19 Versus MIS-C -- Management -- Outpatient Management -- Inpatient Management -- Special Populations -- Antiviral Therapy -- Glucocorticoids -- Nonsteroidal Anti-inflammatory Drugs -- Convalescent Plasma -- Adjunctive Therapy -- Kinase Inhibitors -- Superimposed Infections -- Management of MIS-C -- Guidance for Return to Sports After SARS-CoV-2 Infection -- Vaccines -- References -- Chapter 13 Pharmacologic Therapeutics for COVID-19 -- Virus Life Cycle -- Drug Development for SARS-CoV-2 -- Immune Responses that Contribute to COVID-19 Pathology -- Challenges to Discover and Deploy Drugs for a New Infectious Agent -- Therapeutic Classes -- Antivirals -- Camostat (Foipan) -- Nafamostat -- Upamostat.
|
| 650 |
|
2 |
|a COVID-19
|
| 700 |
1 |
|
|a Gholamrezanezhad, Ali
|e herausgeberin
|0 (DE-588)1290960593
|0 (DE-627)1847049958
|4 edt
|
| 700 |
1 |
|
|a Dube, Michael P.
|e herausgeberin
|4 edt
|
| 776 |
1 |
|
|z 9781119789680
|
| 776 |
0 |
8 |
|i Erscheint auch als
|n Druck-Ausgabe
|a Gholamrezanezhad, Ali
|t Coronavirus Disease 2019 (Covid-19)
|d Newark : John Wiley & Sons, Incorporated,c2023
|z 9781119789680
|
| 856 |
4 |
0 |
|u https://doi.org/10.1002/9781119789741
|m X:WILEY
|x Verlag
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a ISIL_DE-18
|
| 912 |
|
|
|a SYSFLAG_1
|
| 912 |
|
|
|a GBV_KXP
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a GBV_ILN_22_i06404
|
| 951 |
|
|
|a BO
|
| 953 |
|
|
|2 045F
|a 362.1962414
|
| 980 |
|
|
|2 22
|1 01
|x 0018
|b 4252391253
|h h64 Wiley
|k Campuslizenz Universität Hamburg. - Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots.
|y zi06404
|z 27-01-23
|
| 981 |
|
|
|2 22
|1 01
|x 0018
|y Volltextzugang Campus
|r http://dx.doi.org/10.1002/9781119789741
|
| 981 |
|
|
|2 22
|1 01
|x 0018
|y Nur für Angehörige der Universität Hamburg: Volltextzugang von außerhalb des Campus
|r http://emedien.sub.uni-hamburg.de/han/wileyonlinebooks/dx.doi.org/10.1002/9781119789741
|
| 985 |
|
|
|2 22
|1 01
|x 0018
|a uke2023.0085
|
| 985 |
|
|
|2 22
|1 01
|x 0018
|a h64 ebook
|
| 995 |
|
|
|2 22
|1 01
|x 0018
|a h64 Wiley
|
| 995 |
|
|
|2 22
|1 01
|x 0018
|a h64 ACQ
|
| 995 |
|
|
|2 22
|1 01
|x 0018
|a ACQ
|
